Adroit Market Research - Industry Insights
Antibiotics Market By Drug Class (Broad Spectrum Penicillins, Cephalosporins, Macrolides, Quinolones, Tetracyclines, Narrow Spectrum Penicillins, Trimethoprim & Combinations, Others), By Route of Administration, (Oral, Parenteral), and by Region (North America, Europe, Asia-Pacific, Middle East & Africa, and South America), Global Forecast - 2019 to 2028
Jul 2021
Total Pages: 100
Choose License Type
Since their discovery, antibiotics have played an essential role in the treatment of infections in humans and animals, and have significantly improved public health. The use of antibiotics appears to be very high in some parts of the world, suggesting their overuse, whereas it is low in others, which may indicate limited access to these life-saving medicines.
.png "Global Antibiotics Market 2019-2028 (USD Billion)")
The global antibiotics market size is valued at USD 32.70 billion in 2020. Increasing prevalence of infectious diseases and rising disposable income leading to increasing access to antibiotics are the major factors driving the global antibiotics market. However, growing burden of antibiotic resistance and increase in drug approval costs may hamper the market growth.
Key Segments of the Global Antibiotics Market
Drug Class Overview, 2019-2028 (USD Billion)
- Broad Spectrum Penicillins
- Cephalosporins
- Macrolides
- Quinolones
- Tetracyclines
- Narrow Spectrum Penicillins
- Trimethoprim & Combinations
- Others
Route of administration Overview, 2019-2028 (USD Billion)
- Oral
- Parenteral
Regional Overview, 2019-2028 (USD Billion)
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global antibiotics market
- Increasing prevalence of infectious diseases and HAIs
What does the report include?
- The study on the global antibiotics market includes qualitative factors such as drivers, restraints, and opportunities
- The study covers a qualitative and quantitative analysis of the market segmented based on product, and end-use. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments.
- The study covers the competitive landscape of existing/prospective players in the antibiotics industry and their strategic initiatives for product development
Who should buy this report?
- This study is suitable for industry participants and stakeholders in the global antibiotics market
- Every stakeholder involved in developing and distributing pharmaceutical drugs and medicines
- Product managers looking to publish recent and forecasted statistics pertaining to the global antibiotics market
- Government organizations, regulatory authorities, policymakers, and organizations looking for investments in trends of the global antibiotics market
- Analysts, researchers, educators, strategy managers, and government institutions looking for insights into the market to determine future strategies
With the growing antibiotics administration, a parallel upsurge in antimicrobial resistance (AMR) is becoming a major threat to human development as it affects our ability to treat a range of infections caused by bacteria, parasites, viruses and fungi. Patients with resistant infections have to pay higher treatment costs in comparison to patients with non-resistant infection due to extended period of illness, the requirement for exclusive medicines and added tests. In order to tackle the additional burden coming from antimicrobial resistance, many pharmaceutical giants are developing stewardship strategies to monitor the use of antimicrobials in humans and animals, along with the antimicrobial load in the environment. Moreover, these strategies also emphasize on the development of new antimicrobial medicines to substitute those becoming less effective.
Finding the right balance between access and stewardship requires a concerted effort by multiple sectors (including farming and agriculture) and stakeholders (including governments and healthcare professionals). Pharmaceutical companies play a central role, due to their unique proficiency in transforming scientific innovations into capable candidates and arranging marketed products to millions of patients. As a result, it is key to maintain pharmaceutical companies engaged in the efforts to limit AMR. Unfortunately, market incentives to develop and deploy antimicrobials (and, in particular, antibiotics) are weak. Urgent requirement for new antibiotics is the main reason for failure to achieve the desired market is simple. Yet, tight control on the drugs once they reach the market shall limit the risk of emergence of resistance. Moreover, in comparison with other conventional drugs, antibiotics are cheaper and taken for a shorter time period. These factors, together with significant scientific and regulatory hurdles, make high-volume and/or high-margin pharmaceutical markets less likely to develop.
Product Segment
Based on drug class, the global antibiotics market has been segmented into broad spectrum penicillins, cephalosporins, macrolides, quinolones, tetracyclines, narrow spectrum penicillins, trimethoprim & combinations, and others. Broad spectrum penicillins formed the largest segment in 2020, with more than 36% market share, contributing USD 11.99 billion. Broad-spectrum penicillins are invaluable in managing infectious diseases; yet, preventing their overuse is of utmost importance for avoiding infections that are being caused by multidrug-resistant organisms.
In low and middle income countries, broad spectrum antibiotics are randomly used for any condition by means of self-medication or from a chemist prescription. The pharmaceutical industry has a hold of widespread doctors and pharmacists exaggerating the efficiency of broad spectrum antibiotics and the message has filtered down to the end users. Medical practitioners are prescribing any available antibiotic for diseases such as typhoid, food poisoning and cholera. The perpetrator responsible in this situation is solely the authorities, which have failed to standardize regulations upholding the antibiotics market.
In India, fixed-dose combinations, of anti-amoebics like tinidazole and anti-bacterials like ciprofloxacin have become prevalent and are being used for all microbial diarrhoea. However, 90% of these diarrhoea cases are due to viruses and do not need medication. The remaining 9% cases are a result of bacterial or amoeba infection needing any anti-bacterial or an anti-amoebic, while the remaining 1% is due to a combination of bacteria and amoeba which requires a drug combination. Moreover, it turns out that only drug combinations are being used to treat all diarrhoea cases. These drug combinations are only marketed in India due to the negligent domestic regulations.
North America dominated the global antibiotics market in 2020. In 2015, doctors' offices, emergency rooms, and other outpatient settings in the United States prescribed over 270 million antibiotic prescriptions, resulting in an antibiotic prescription rate of 838 per 1,000 persons. Prescription rates, on the other hand, vary considerably between states, with larger numbers in the South and lower numbers in the West.
.png "Asia Pacific Antibiotics Market 2019-2028 (USD Billion)")
However, Asia Pacific is set to grow at a highest pace with a CAGR of 5.8% during the forecast years. Countries like India and China are among the prominent antibiotic consumers in the Asian region. There is a country wide income rise in these nations leading to increased ability to purchase antibiotics, along with large population base. Moreover, lax regulations governing antibiotics is the prime driver for antibiotics market in these countries.
Furthermore, growing antibiotic consumption, is the main cause for the burden of antimicrobial resistance (AMR), where bacteria increasingly becomes resistant to the drugs. India, hence, dominates the AMR burden. The prescription rates of antibiotics is although, less in the country as compared to the other regions, however when it comes to third and fourth line antibiotics, India taps a many countries.
Since their discovery, antibiotics have played an essential role in the treatment of infections in humans and animals, and have significantly improved public health. The use of antibiotics appears to be very high in some parts of the world, suggesting their overuse, whereas it is low in others, which may indicate limited access to these life-saving medicines.
The global antibiotics market size is valued at USD 32.70 billion in 2020. Increasing prevalence of infectious diseases and rising disposable income leading to increasing access to antibiotics are the major factors driving the global antibiotics market. However, growing burden of antibiotic resistance and increase in drug approval costs may hamper the market growth.
Key Segments of the Global Antibiotics Market
Drug Class Overview, 2019-2028 (USD Billion)
- Broad Spectrum Penicillins
- Cephalosporins
- Macrolides
- Quinolones
- Tetracyclines
- Narrow Spectrum Penicillins
- Trimethoprim & Combinations
- Others
Route of administration Overview, 2019-2028 (USD Billion)
- Oral
- Parenteral
Regional Overview, 2019-2028 (USD Billion)
North America
- U.S.
- Canada
Europe
- UK
- Germany
- France
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
South America
- Brazil
- Mexico
- Rest of South America
Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
Reasons for the study
- The purpose of the study is to give an exhaustive outlook of the global antibiotics market
- Increasing prevalence of infectious diseases and HAIs
What does the report include?
- The study on the global antibiotics market includes qualitative factors such as drivers, restraints, and opportunities
- The study covers a qualitative and quantitative analysis of the market segmented based on product, and end-use. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments.
- The study covers the competitive landscape of existing/prospective players in the antibiotics industry and their strategic initiatives for product development
Who should buy this report?
- This study is suitable for industry participants and stakeholders in the global antibiotics market
- Every stakeholder involved in developing and distributing pharmaceutical drugs and medicines
- Product managers looking to publish recent and forecasted statistics pertaining to the global antibiotics market
- Government organizations, regulatory authorities, policymakers, and organizations looking for investments in trends of the global antibiotics market
- Analysts, researchers, educators, strategy managers, and government institutions looking for insights into the market to determine future strategies
1. Introduction
1.1. Introduction
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. High incidence of infectious diseases
3.2.1.2. Wide availability of generics
3.2.2. Restraints
3.2.2.1. Economic barriers of antibiotic R&D
3.2.2.2. Misuse of antibiotics and resistance crisis
3.2.3. Opportunities
3.2.3.1. Introduction of new approaches for managing bacterial infections
3.3. Porter’s Five Forces Analysis
3.4. Value Chain Analysis
3.5. Regulatory Framework
3.6. COVID-19 Impact Analysis
4. Antibiotics Market by Drug Class, 2019-2028 (USD Billion)
4.1. Global antibiotics market revenue share, by drug class, 2020 & 2028 (%)
4.2. Broad Spectrum Penicillins
4.2.1. Global market size and projections, 2019-2028
4.3. Cephalosporins
4.3.1. Global market size and projections, 2019-2028
4.4. Macrolides
4.4.1. Global market size and projections, 2019-2028
4.5. Quinolones
4.5.1. Global market size and projections, 2019-2028
4.6. Tetracyclines
4.6.1. Global market size and projections, 2019-2028
4.7. Narrow Spectrum Penicillins
4.7.1. Global market size and projections, 2019-2028
4.8. Trimethoprim & Combinations
4.8.1. Global market size and projections, 2019-2028
4.9. Others
4.9.1. Global market size and projections, 2019-2028
5. Antibiotics Market by Route of Administration, 2019-2028 (USD Billion)
5.1. Global antibiotics market revenue share, by route of administration, 2020 & 2028 (%)
5.2. Oral
5.2.1. Global market size and projections, 2019-2028
5.3. Parenteral
5.3.1. Global market size and projections, 2019-2028
6. Antibiotics Market by Region, 2019-2028 (USD Billion)
6.1. Global antibiotics market revenue share, by region, 2020 & 2028 (%)
6.2. North America
6.2.1. North America antibiotics market size and projections, by country, 2019-2028
6.2.2. North America antibiotics market size and projections, by drug class, 2019-2028
6.2.3. North America antibiotics market size and projections, by route of administration, 2019-2028
6.2.4. US
6.2.4.1. U.S. antibiotics market size and projections, 2019-2028
6.2.5. Canada
6.2.5.1. Canada antibiotics market size and projections, 2019-2028
6.3. Europe
6.3.1. Europe antibiotics market size and projections, by country, 2019-2028
6.3.2. Europe antibiotics market size and projections, by drug class, 2019-2028
6.3.3. Europe antibiotics market size and projections, by route of administration, 2019-2028
6.3.4. UK
6.3.4.1. UK antibiotics market size and projections, 2019-2028
6.3.5. Germany
6.3.5.1. Germany antibiotics market size and projections, 2019-2028
6.3.6. France
6.3.6.1. France antibiotics market size and projections, 2019-2028
6.3.7. Rest of Europe
6.3.7.1. Rest of Europe antibiotics market size and projections, 2019-2028
6.4. Asia Pacific
6.4.1. Asia Pacific antibiotics market size and projections, by country, 2019-2028
6.4.2. Asia Pacific antibiotics market size and projections, by drug class, 2019-2028
6.4.3. Asia Pacific antibiotics market size and projections, by route of administration, 2019-2028
6.4.4. China
6.4.4.1. China antibiotics market size and projections, 2019-2028
6.4.5. Japan
6.4.5.1. Japan antibiotics market size and projections, 2019-2028
6.4.6. India
6.4.6.1. India antibiotics market size and projections, 2019-2028
6.4.7. Rest of APAC
6.4.7.1. Rest of APAC antibiotics market size and projections, 2019-2028
6.5. Latin America
6.5.1. Latin America antibiotics market size and projections, by country, 2019-2028
6.5.2. Latin America antibiotics market size and projections, by drug class, 2019-2028
6.5.3. Latin America antibiotics market size and projections, by route of administration, 2019-2028
6.5.4. Brazil
6.5.4.1. Brazil antibiotics market size and projections, 2019-2028
6.5.5. Mexico
6.5.5.1. Mexico antibiotics market size and projections, 2019-2028
6.5.6. Rest of Latin America
6.5.6.1. Rest of Latin America antibiotics market size and projections, 2019-2028
6.6. Middle East & Africa
6.6.1. Middle East & Africa antibiotics market size and projections, by country, 2019-2028
6.6.2. Middle East & Africa antibiotics market size and projections, by drug class, 2019-2028
6.6.3. Middle East & Africa antibiotics market size and projections, by route of administration, 2019-2028
6.6.4. GCC
6.6.4.1. GCC antibiotics market size and projections, 2019-2028
6.6.5. South Africa
6.6.5.1. South Africa antibiotics market size and projections, 2019-2028
6.6.6. Rest of MEA
6.6.6.1. Rest of MEA antibiotics market size and projections, 2019-2028
7. Company Profiles
7.1. Abbott Laboratories
7.1.1. Overview
7.1.2. Products Portfolio
7.1.3. Recent Initiatives
7.1.4. Company Financials
7.2. F.Hoffmann-La Roche Ltd.
7.2.1. Overview
7.2.2. Products Portfolio
7.2.3. Recent Initiatives
7.2.4. Company Financials
7.3. GlaxoSmithKline Plc.
7.3.1. Overview
7.3.2. Products Portfolio
7.3.3. Recent Initiatives
7.3.4. Company Financials
7.4. Merck & Co. Inc.
7.4.1. Overview
7.4.2. Products Portfolio
7.4.3. Recent Initiatives
7.4.4. Company Financials
7.5. Mylan N.V.
7.5.1. Overview
7.5.2. Products Portfolio
7.5.3. Recent Initiatives
7.5.4. Company Financials
7.6. Novartis International AG
7.6.1. Overview
7.6.2. Products Portfolio
7.6.3. Recent Initiatives
7.6.4. Company Financials
7.7. Pfizer Inc.
7.7.1. Overview
7.7.2. Products Portfolio
7.7.3. Recent Initiatives
7.7.4. Company Financials
7.8. Sanofi
7.8.1. Overview
7.8.2. Products Portfolio
7.8.3. Recent Initiatives
7.8.4. Company Financials
7.9. Teva Pharmaceutical Industries Ltd.
7.9.1. Overview
7.9.2. Products Portfolio
7.9.3. Recent Initiatives
7.9.4. Company Financials
7.10. Cipla Ltd.
7.10.1. Overview
7.10.2. Products Portfolio
7.10.3. Recent Initiatives
7.10.4. Company Financials